File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1182/hematology.2023000452
- Scopus: eid_2-s2.0-85179640735
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations
Title | Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations |
---|---|
Authors | |
Issue Date | 8-Dec-2023 |
Publisher | American Society of Hematology |
Citation | Hematology, 2023, v. 2023, n. 1, p. 667-675 How to Cite? |
Abstract | Myeloproliferative neoplasms (MPNs) are characterized by clonal myeloproliferation in 1 or more of the hematopoietic stem cell lineages. Primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF have the worst prognosis and are characterized by the presence of cytokine-mediated symptom complex, splenomegaly, progressive marrow failure, and clonal instability, leading to leukemic transformation. The key therapeutic aims encompass the management of symptoms, splenomegaly, and anemia and the improvement of survivals. These therapeutic aims have evolved with the availability of Jak inhibitors and novel agents, making disease modification potentially achievable. Novel agents may potentially target MPN stem cells, epigenetic alterations, signaling pathways, and apoptotic pathways. In this case-based review, we outline our approach to the management of MF and discuss the therapeutic landscape of MF, highlighting the utility of Jak inhibitors and novel Jak inhibitor-based combinations. |
Persistent Identifier | http://hdl.handle.net/10722/339670 |
ISSN | 2023 Impact Factor: 2.9 2023 SCImago Journal Rankings: 1.139 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Singh, Gill Harinder Harry | - |
dc.contributor.author | Leung, Man Kit Garret | - |
dc.contributor.author | Kwong, Yok Lam | - |
dc.date.accessioned | 2024-03-11T10:38:25Z | - |
dc.date.available | 2024-03-11T10:38:25Z | - |
dc.date.issued | 2023-12-08 | - |
dc.identifier.citation | Hematology, 2023, v. 2023, n. 1, p. 667-675 | - |
dc.identifier.issn | 1520-4391 | - |
dc.identifier.uri | http://hdl.handle.net/10722/339670 | - |
dc.description.abstract | <p> <span>Myeloproliferative neoplasms (MPNs) are characterized by clonal myeloproliferation in 1 or more of the hematopoietic stem cell lineages. Primary myelofibrosis (MF), post-polycythemia vera MF, and post-essential thrombocythemia MF have the worst prognosis and are characterized by the presence of cytokine-mediated symptom complex, splenomegaly, progressive marrow failure, and clonal instability, leading to leukemic transformation. The key therapeutic aims encompass the management of symptoms, splenomegaly, and anemia and the improvement of survivals. These therapeutic aims have evolved with the availability of Jak inhibitors and novel agents, making disease modification potentially achievable. Novel agents may potentially target MPN stem cells, epigenetic alterations, signaling pathways, and apoptotic pathways. In this case-based review, we outline our approach to the management of MF and discuss the therapeutic landscape of MF, highlighting the utility of Jak inhibitors and novel Jak inhibitor-based combinations.</span> <br></p> | - |
dc.language | eng | - |
dc.publisher | American Society of Hematology | - |
dc.relation.ispartof | Hematology | - |
dc.title | Evolving landscape of JAK inhibition in myelofibrosis: monotherapy and combinations | - |
dc.type | Article | - |
dc.identifier.doi | 10.1182/hematology.2023000452 | - |
dc.identifier.scopus | eid_2-s2.0-85179640735 | - |
dc.identifier.volume | 2023 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 667 | - |
dc.identifier.epage | 675 | - |
dc.identifier.eissn | 1520-4383 | - |
dc.identifier.issnl | 1520-4383 | - |